

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

CHENG ET AL.

APPLICATION NO: 10/616,365

Burton Rodney Type or print name

FILED: JULY 8, 2003

FOR: SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS

ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD

MAIL STOP: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the documents cited on the attached form(s) PTO-1449.

Copies of these documents are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each document was considered by returning a copy of the initialed PTO 1449 form(s).

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 (609) 252-4336

Date: 10/29/03

Respectfully submitted,

Burton Rodney Attorney for Applicants

Reg. No. 22,076

FORM PTO-1449
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

(Use Exercisheets if necessary)

ATTY. DOCKET NO. LA0089 NP APPLICATION NO. 10/616,365 APPLICANT CHENG ET AL. FILING DATE JULY 8, 2003

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	6,414,002	7/2/02	Cheng et al.			
	AB		-				
	AC						
	AD						
	AE						
	AF						
	AG						
	АН						
	Al			_			
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
AM	0 520 723	6/1/94	EP	·			
AN	WO 92/22533	12/23/92	PCT				
AO	WO 95/18130	7/6/95	PCT				
AP	WO 96/38415	12/5/96	PCT				
AQ	WO 97/00258	1/3/97	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Cobb, J.E. et al., "N-(2-Benzoylphenyl)-L-tyrosine PPAR _γ Agonists. 3. Structure-Activity Relationship and Optimization of the N-Aryl Substituent", J. Med. Chem., Vol. 41, pp. 5055-5069 (1998)
<u> </u>	AS	Collins, J.L. et al., "N-(2-Benzoylphenyl)-L-tyrosine PPAR Agonists. 2. Structure-Activity Relationship and Optimization of the Phenyl Alkyl Ether Moiety", J. Med. Chem., Vol. 41, pp. 5037-5054 (1998)
	АТ	Henke, B.R. et al., "N-(2-Benzoylphenyl)-L-tyrosine PPARγ Agonists. 1. Discovery of a Novel Series of Potent Antihyperglycemic and Antihyperlipidemic Agents", J. Med. Chem., Vol. 41, pp. 5020-5036 (1998)

EXAMINER

DATE CONSIDERED

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)
PINEFORMATI
(Use several s

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

séveval sheets if necessary)

ATTY. DOCKET NO. LA0089 NP APPLICATION NO. 10/616,365 APPLICANT CHENG ET AL. FILING DATE JULY 8, 2003

Group

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLAS		SLATION
	2AA	WO 97/27847	8/7/97	PCT		S	YES	NO
	2AB	WO 97/27857	8/7/97	PCT	. ,			
	2AC	WO 97/28137	8/7/97	PCT			H	
	2AD	WO 97/28149	8/7/97	PCT			計	1 -
	2AE	WO 97/31907	9/4/97	PCT				
	2AF	WO 98/00137	1/8/98	PCT		-		
	2AG	WO 98/00403	1/8/98	PCT				
	2AH	WO 98/27974	7/2/98	PCT				
	2AI	WO 99/07357	2/18/99	PCT				
	2AJ	WO 99/08501	2/25/99	PCT				
	2AK	WO 99/11255	3/11/99	PCT				
	2AL	WO 99/15520	4/1/99	PCT				
	2AM	WO 99/16758	4/8/99	PCT			H	
	2AN	WO 99/16770	4/8/99	PCT			 	
	2AO	WO 99/20275	4/29/99	PCT				
	2AP	WO 99/46232	9/16/99	PCT			Ħ	
	2AQ	WO 00/08002	2/17/00	PCT			 -	
1-10	2AR	WO 00/64876	11/2/00	PCT			Ħ	
	2AS	WO 00/64888	11/2/00	PCT				 - - - - - - - -
	2AT	WO 01/38325	5/31/01	PCT			后	† =
	AU		<u> </u>					
	AV							
	AW							
	AX							
	AY							
	AZ							
EXA	MINER	<u> </u>	<u> </u>	DATE CONSIDERED		<u></u>		

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.